2015
DOI: 10.1007/s12028-015-0222-x
|View full text |Cite
|
Sign up to set email alerts
|

Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage

Abstract: This guideline provides timely, evidence-based reversal strategies to assist practitioners in the care of patients with antithrombotic-associated intracranial hemorrhage.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
245
2
2

Year Published

2016
2016
2022
2022

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 582 publications
(250 citation statements)
references
References 416 publications
1
245
2
2
Order By: Relevance
“…Current NCS guidelines recommend using activated charcoal and PCC if needed for direct factor Xa inhibitor-related ICH. They recommend use of Idarucizumab for dabigatran-related ICH, which is supported by animal and current human studies (131). …”
Section: Hematoma Expansionmentioning
confidence: 94%
See 2 more Smart Citations
“…Current NCS guidelines recommend using activated charcoal and PCC if needed for direct factor Xa inhibitor-related ICH. They recommend use of Idarucizumab for dabigatran-related ICH, which is supported by animal and current human studies (131). …”
Section: Hematoma Expansionmentioning
confidence: 94%
“…The clinical benefit would have to outweigh the side effect of arterial thrombosis and the right dose and clinical setting would need to be narrowly defined. Currently, AHA/ASA and neurocritical care society (NCS) guidelines recommend against use of rFVIIa in ICH patients (1, 131). …”
Section: Hematoma Expansionmentioning
confidence: 99%
See 1 more Smart Citation
“…Of note, in a retrospective study of 18 TBI patients with either ICH or subarachnoid hemorrhage who were taking either rivaroxaban or apixaban, 4-factor prothrombin complex concentrate was safely used to potentially reduce hematoma expansion [36]. The Neurocritical Care Society (NCS) has recently released guidelines for the rapid reversal of antithrombotics in ICH [37], the principles of which may serve as a guide for sTBI management as well.…”
Section: Emergency Department Considerationsmentioning
confidence: 99%
“…These include general-use agents, such as four-factor prothrombin complex concentrates (72) (trade name Kcentra, approved for use in the United States in 2013), and targeted drugs, such as the antibody idarucizumab (trade name Praxibind, approved for use in the United States in 2015), which inactivates dabigatran (73). As a result, although guidelines exist for the reversal of anticoagulation in SICH, the majority of these are good-practice recommendations without extensive, high-quality supporting evidence (74). …”
Section: Translational Therapiesmentioning
confidence: 99%